Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Keywords

ClinConnect Summary

The accuracy of skin testing to detect Mycobacterium tuberculosis (MTb) infection is dependent upon the host's ability to mount a delayed-type hypersensitivity (DTH) reaction; however, the DTH response may be impaired or absent in patients with impaired cell-mediated immunity, a classic characteristic of HIV infection. Patients in whom immunity is diminished, but not absent, may test negative the first time a purified protein derivative skin test for MTb is administered, but if the same skin test is repeated, a positive DTH response may then be elicited. This occurrence is known as the "boo...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients must have:
• • HIV infection.
• • Negative PPD skin test within previous 7-28 days.
• • Exclusion Criteria
• Concurrent Medication:
• Excluded:
• • Steroids.
• • Live viral vaccines.
• • Antihistamines.
• • Chemoprophylaxis or chemotherapy for suspected or confirmed tuberculosis.
• Patients with the following prior conditions are excluded:
• • History of documented positive PPD skin test.
• • History of tuberculosis or who are presently receiving chemoprophylaxis or chemotherapy for suspected or confirmed tuberculosis.
• • History of sensitivity to tuberculin or components of PPD.
• Prior Medication:
• Excluded:
• • Live viral vaccine within the past 4 weeks.
• • Steroid therapy within the past 4 weeks.
• • Antihistamines within the past week.
• • Chemoprophylaxis or chemotherapy for suspected or confirmed tuberculosis.